Galmed Pharmaceuticals (GLMD) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Galmed Pharmaceuticals is conducting a Phase I open-label trial titled ‘Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meglumine Tablet.’ The study aims to evaluate the exposure of Aramchol from two different single doses of an Aramchol meglumine tablet and compare the steady-state exposure from a selected dose. This research is significant for understanding the pharmacokinetics of Aramchol, which could inform future therapeutic applications.
The intervention being tested is the Aramchol meglumine tablet, a drug designed to assess plasma concentration levels at varying doses. The study involves two parts: Part A tests two different single doses, while Part B assesses the steady-state plasma concentration over ten days.
The study is designed as a non-randomized, crossover trial with an open-label format, meaning no blinding is involved. Participants will attend two trial sessions with a 14-day washout period between doses. The primary purpose of the study is treatment-focused.
Key dates for this study include a start date of November 14, 2025, and the last update was submitted on November 24, 2025. The study is not yet recruiting, indicating that participant enrollment has not begun.
The market implications of this study update could influence Galmed Pharmaceuticals’ stock performance, as successful outcomes may enhance investor confidence and competitive positioning in the pharmaceutical industry. Investors should monitor this study’s progress for potential impacts.
The study is ongoing, with further details available on the ClinicalTrials portal.
To learn more about GLMD’s potential, visit the Galmed Pharmaceuticals drug pipeline page.